1. 1) Nath SK, Salama S, Persaud D, Thornley JH, Smith I, Foster G, Rotstein C. Drug risk factors associated with a sustained outbreak of Clostridium difficile diarrhea in a teaching hospital. Can. J. Infect. Dis., 5, 270–275 (1994).
2. 2) Hung YP, Ko WC, Chou PH, Chen YH, Lin HJ, Liu YH, Tsai HW, Lee JC, Tsai PJ. Proton-Pump Inhibitor Exposure Aggravates Clostridium difficile-Associated Colitis: Evidence from a Mouse Model. J. Infect. Dis., 212, 654–663 (2015).
3. 3) Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med., 370, 1198–1208 (2014).
4. 4) Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect. Dis., 17, 990–1001 (2017).
5. 5) Riley TV, Kimura T. The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review. Infect. Dis. Ther., 7, 39–70 (2018).